As of 2026-02-18, the Intrinsic Value of Arix Bioscience PLC (ARIX.L) is 34.02 GBP. This ARIX.L valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 142.00 GBP, the upside of Arix Bioscience PLC is -76.00%.
The range of the Intrinsic Value is 40.64 - 23.02 GBP
Based on its market price of 142.00 GBP and our intrinsic valuation, Arix Bioscience PLC (ARIX.L) is overvalued by 76.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (99.19) - 10.21 | (18.50) | -113.0% |
| DCF (Growth 10y) | 10.12 - (83.66) | (14.72) | -110.4% |
| DCF (EBITDA 5y) | 40.64 - 23.02 | 34.02 | -76.0% |
| DCF (EBITDA 10y) | 32.24 - 14.37 | 25.37 | -82.1% |
| Fair Value | 288.99 - 288.99 | 288.99 | 103.51% |
| P/E | 117.68 - 210.39 | 160.39 | 13.0% |
| EV/EBITDA | 49.35 - 34.84 | 44.93 | -68.4% |
| EPV | 33.27 - 20.15 | 26.71 | -81.2% |
| DDM - Stable | 126.29 - 457.26 | 291.78 | 105.5% |
| DDM - Multi | (263.53) - (742.74) | (389.13) | -374.0% |
| Market Cap (mil) | 183.73 |
| Beta | 0.37 |
| Outstanding shares (mil) | 1.29 |
| Enterprise Value (mil) | 82.78 |
| Market risk premium | 5.98% |
| Cost of Equity | 8.34% |
| Cost of Debt | 5.00% |
| WACC | 8.34% |